Products
Deferasirox is commercially available in the form of film-coated tablets (Jadenu, generic). It was approved in many countries in 2005. Exjade is no longer marketed.
Structure and properties
Deferasirox (C21H15N3O4, Mr = 373.4 g/mol)
Effects
Deferasirox (ATC V03AC03) is an orally active chelator with high selectivity for trivalent iron. It is a three-armed ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes the excretion of iron via bile. It also has a lower affinity for aluminum and a much lower affinity for zinc and copper.
Indications
- Transfusion-related hemosiderosis.
- Chronic iron overload requiring chelation therapy in patients with nontransfusion-dependent thalassemia aged 10 years and older.
